» Articles » PMID: 35402018

Tomotherapy-based Moderate Hypofractionation for Localized Prostate Cancer: a Mono-institutional Analysis

Overview
Specialty Oncology
Date 2022 Apr 11
PMID 35402018
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To date, few studies have been published on image-guided helical tomotherapy (HT) in a moderate hypofractionation of localized PCa. We report outcome and toxicity of localized PCa patients treated with HT-based moderate hypofractionated radiotherapy.

Materials And Methods: 76 patients were retrospectively analyzed. A total dose of 60 Gy (20 × 3 Gy) or 67.5 Gy (25 × 2.7 Gy) was prescribed. The χ test was used to analyze associations between toxicity and dosimetric and clinical parameters. The Cox proportional hazard regression model was used for multivariate analysis. Kaplan-Meier method was used for survival analysis.

Results: median follow-up was 42.26 months [interquartile (IQR), 23-76). At 4-year, overall survival (OS) and metastasis-free survival (MFS) were 91% and 89%, respectively. At multivariate analysis, smoking habitude was associated with MFS [hazard ratio (HR) 7.32, 95% CI: 1.57-34.16, p = 0.011]. Acute and late grade ≥ 2 gastro-intestinal (GI) toxicity was observed in 6.5% and 2.6% of patients, respectively. Acute and late grade ≥ 2 genito-urinary (GU) toxicity were 31.5% and 3.9%. Four-year late GI and GU grade ≥ 2 toxicity were 3% and 7%, respectively. Acute GI toxicity was associated with statins medication (p = 0.04) and androgen deprivation therapy (p = 0.013). Acute GU toxicity was associated with the use of anticoagulants (p = 0.029) and antiaggregants (p = 0.013).

Conclusions: HT-based moderate hypofractionation shows very low rates of toxicity. Smoking habitude is associated with the risk of developing metastases after radical treatment for localized PCa.

Citing Articles

Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.

Cozzi S, Ruggieri M, Ali E, Finocchi Ghersi S, Vigo F, Augugliaro M In Vivo. 2023; 37(2):777-785.

PMID: 36881094 PMC: 10026640. DOI: 10.21873/invivo.13141.


Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer.

Piotrowski T, Yartsev S, Krawczyk J, Adamczyk M, Jodda A, Malicki J Life (Basel). 2022; 12(3).

PMID: 35330145 PMC: 8951141. DOI: 10.3390/life12030394.

References
1.
Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M . Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008; 71(4):1065-73. DOI: 10.1016/j.ijrobp.2007.11.037. View

2.
Cekani E, Lopez-Guerra J, Barrientos R, Tavera P, Praena-Fernandez J, Rivin Del Campo E . Late toxicity for prostate cancer patients treated with hypofractionated helical tomotherapy. Rep Pract Oncol Radiother. 2019; 24(3):298-305. PMC: 6510972. DOI: 10.1016/j.rpor.2019.04.001. View

3.
Crivelli J, Xylinas E, Kluth L, Rieken M, Rink M, Shariat S . Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2013; 65(4):742-54. DOI: 10.1016/j.eururo.2013.06.010. View

4.
Cuccia F, Mortellaro G, Trapani G, Valenti V, Ognibene L, De Gregorio G . Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis. Radiol Med. 2019; 125(2):220-227. DOI: 10.1007/s11547-019-01095-9. View

5.
Palumbo I, Matrone F, Montesi G, Bellavita R, Lupattelli M, Saldi S . Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study. Anticancer Res. 2017; 37(3):1453-1457. DOI: 10.21873/anticanres.11469. View